GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (FRA:41O) » Definitions » Deferred Policy Acquisition Costs

Outlook Therapeutics (FRA:41O) Deferred Policy Acquisition Costs


View and export this data going back to 2019. Start your Free Trial

What is Outlook Therapeutics Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Outlook Therapeutics (FRA:41O) Business Description

Industry
Traded in Other Exchanges
Address
485 Route 1 South Building F, Suite 320, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.